top of page


Helus Pharma reports positive Phase III HLP003 results in major depressive disorder
Helus Pharma has reported positive Phase III results for investigational deuterated psilocin treatment HLP003 in major depressive disorder, with statistically significant improvements in depression scores through 12 weeks.

nuaxia
1 hour ago2 min read


Johnson & Johnson agrees to acquire Ollin Biosciences for up to $3.3 billion to expand retinal disease pipeline
Johnson & Johnson has agreed to acquire ophthalmology biotechnology company Ollin Biosciences for up to approximately $3.3 billion, adding a Phase III retinal disease antibody programme alongside a separate $750 million Blackstone development funding arrangement.

nuaxia
1 hour ago2 min read
bottom of page